JP2020007318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020007318A5 JP2020007318A5 JP2019148550A JP2019148550A JP2020007318A5 JP 2020007318 A5 JP2020007318 A5 JP 2020007318A5 JP 2019148550 A JP2019148550 A JP 2019148550A JP 2019148550 A JP2019148550 A JP 2019148550A JP 2020007318 A5 JP2020007318 A5 JP 2020007318A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- binding molecule
- aspects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022167816A JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168941 | 2013-05-23 | ||
| EP13168941.6 | 2013-05-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515304A Division JP2016520313A (ja) | 2013-05-23 | 2014-05-22 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167816A Division JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020007318A JP2020007318A (ja) | 2020-01-16 |
| JP2020007318A5 true JP2020007318A5 (enExample) | 2020-09-03 |
| JP7163254B2 JP7163254B2 (ja) | 2022-10-31 |
Family
ID=48485015
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515304A Pending JP2016520313A (ja) | 2013-05-23 | 2014-05-22 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
| JP2019148550A Active JP7163254B2 (ja) | 2013-05-23 | 2019-08-13 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
| JP2022167816A Active JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515304A Pending JP2016520313A (ja) | 2013-05-23 | 2014-05-22 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167816A Active JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9944717B2 (enExample) |
| EP (2) | EP2999714B1 (enExample) |
| JP (3) | JP2016520313A (enExample) |
| CN (1) | CN105492461B (enExample) |
| AU (1) | AU2014269193C1 (enExample) |
| CA (1) | CA2913318C (enExample) |
| DK (2) | DK2999714T3 (enExample) |
| ES (2) | ES2904709T3 (enExample) |
| HU (2) | HUE057858T2 (enExample) |
| LT (2) | LT2999714T (enExample) |
| MX (1) | MX366046B (enExample) |
| PL (2) | PL2999714T3 (enExample) |
| PT (2) | PT3725803T (enExample) |
| WO (1) | WO2014189378A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| ES2904709T3 (es) * | 2013-05-23 | 2022-04-05 | Broteio Pharma B V | Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas |
| CN110300520B (zh) * | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| CN113260375B (zh) * | 2018-12-13 | 2024-10-01 | 阿尔金克斯有限公司 | 针对人补体因子C2b的抗体及使用方法 |
| GB2584105B (en) | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| AU2020330307A1 (en) * | 2019-08-12 | 2022-03-17 | CSL Innovation Pty Ltd | Complement C2 binding proteins and uses thereof |
| CA3237883A1 (en) * | 2022-01-29 | 2023-08-03 | Kira Pharmaceuticals (Suzhou) Ltd. | Anti-c2 antibodies and uses thereof |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
| WO2025260123A1 (en) * | 2024-06-17 | 2025-12-26 | CSL Innovation Pty Ltd | Anti-c2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| ES2904709T3 (es) * | 2013-05-23 | 2022-04-05 | Broteio Pharma B V | Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas |
-
2014
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
-
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
-
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
-
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020007318A5 (enExample) | ||
| US11518815B2 (en) | Anti-ROR1 antibodies and methods of making and using thereof | |
| JP7393337B2 (ja) | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 | |
| JP6862435B2 (ja) | 抗ｗｔ１／ｈｌａ特異的抗体 | |
| JP7476997B2 (ja) | 二重特異性抗体 | |
| JP6009431B2 (ja) | アフィニティー精製の方法 | |
| JP5727133B2 (ja) | 抗イディオタイプ抗体を得る方法 | |
| JP2022510322A (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN102264391A (zh) | 工程化抗il-13抗体、组合物、方法和用途 | |
| JP7002145B2 (ja) | 抗ｃｄ１０抗体 | |
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| TWI681971B (zh) | 新穎抗人類Ｉｇβ抗體 | |
| Salemi et al. | The expanding role of therapeutic antibodies | |
| JP2007529196A5 (enExample) | ||
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| KR20100074181A (ko) | β-아밀로이드 펩티드에 대한 인간화 항체 | |
| WO2022267936A1 (zh) | 特异性结合糖基化ceacam5的抗体 | |
| CN118702814B (zh) | 一种抗ngf单克隆抗体及其应用 | |
| CN116554323A (zh) | 人源化抗il21抗体的开发和应用 | |
| JP2023550628A5 (enExample) | ||
| CN110114370B (zh) | 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段 | |
| WO2025086564A1 (zh) | 抗人vsig4的抗体及其医药用途 | |
| US20220153845A1 (en) | A method for immunosuppression | |
| CN118745226B (zh) | 抗ror1抗体及其应用 | |
| CN121449744A (zh) | 抗cd74抗体及其应用 |